JP2024521878A - 置換インドール化合物及びその使用方法 - Google Patents

置換インドール化合物及びその使用方法 Download PDF

Info

Publication number
JP2024521878A
JP2024521878A JP2023574119A JP2023574119A JP2024521878A JP 2024521878 A JP2024521878 A JP 2024521878A JP 2023574119 A JP2023574119 A JP 2023574119A JP 2023574119 A JP2023574119 A JP 2023574119A JP 2024521878 A JP2024521878 A JP 2024521878A
Authority
JP
Japan
Prior art keywords
methyl
alkyl
cycloalkyl
heterocyclyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521878A5 (OSRAM
Inventor
シェン，タオ
ディン，ジンユエ
ゴメス，ロバート
アンドリュー パウエル，デイビッド
エリザベス ローズ，ビクトリア
アントン マテイコ，ニコラス
ピー． ベストファーター，ブライアン
オイケ，タロウ
Original Assignee
チヌーク セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チヌーク セラピューティクス，インコーポレイテッド filed Critical チヌーク セラピューティクス，インコーポレイテッド
Publication of JP2024521878A publication Critical patent/JP2024521878A/ja
Publication of JP2024521878A5 publication Critical patent/JP2024521878A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP2023574119A 2021-06-03 2022-06-03 置換インドール化合物及びその使用方法 Pending JP2024521878A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163196339P 2021-06-03 2021-06-03
US63/196,339 2021-06-03
US202163290019P 2021-12-15 2021-12-15
US63/290,019 2021-12-15
US202263346120P 2022-05-26 2022-05-26
US63/346,120 2022-05-26
PCT/US2022/032042 WO2022256586A2 (en) 2021-06-03 2022-06-03 Substituted indole compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024521878A true JP2024521878A (ja) 2024-06-04
JP2024521878A5 JP2024521878A5 (OSRAM) 2025-06-02

Family

ID=84323595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574119A Pending JP2024521878A (ja) 2021-06-03 2022-06-03 置換インドール化合物及びその使用方法

Country Status (19)

Country Link
US (2) US20240287034A1 (OSRAM)
EP (1) EP4346812A4 (OSRAM)
JP (1) JP2024521878A (OSRAM)
KR (1) KR20240017004A (OSRAM)
CN (1) CN120081822A (OSRAM)
AU (1) AU2022283903A1 (OSRAM)
BR (1) BR112023025235A2 (OSRAM)
CA (1) CA3222144A1 (OSRAM)
CL (1) CL2023003591A1 (OSRAM)
CO (1) CO2023016557A2 (OSRAM)
CR (1) CR20230564A (OSRAM)
DO (1) DOP2023000263A (OSRAM)
EC (1) ECSP23090260A (OSRAM)
IL (1) IL308835A (OSRAM)
JO (1) JOP20230315A1 (OSRAM)
MX (1) MX2023014274A (OSRAM)
PE (1) PE20250114A1 (OSRAM)
PH (1) PH12023553130A1 (OSRAM)
WO (1) WO2022256586A2 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230286947A1 (en) * 2020-08-07 2023-09-14 Shanghai Meiyue Biotech Development Co. Ltd Complement factor b inhibitor, and pharmaceutical composition, preparation method and use thereof
JP7641388B2 (ja) * 2020-12-30 2025-03-06 エス－インフィニティ ファーマシューティカルズ カンパニー リミテッド 一連のピペリジン置換安息香酸系化合物及びその使用
EP4362933A4 (en) * 2021-06-30 2025-06-04 Apellis Pharmaceuticals, Inc. COMPLEMENT INHIBITION
CA3229360A1 (en) 2021-08-18 2023-02-23 Chen Zhang Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
EP4423076A4 (en) * 2021-10-27 2026-01-07 Hansoh Bio Llc PIPERIDINYL INDOLE DERIVATIVES, THEIR PREPARATION PROCESSES AND MEDICAL USES
CR20240300A (es) * 2022-01-24 2024-08-23 Novartis Ag Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos.
CN119301114A (zh) * 2022-06-07 2025-01-10 正大天晴药业集团股份有限公司 双环取代的芳香羧酸类氘代化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
CN119546585A (zh) * 2022-06-23 2025-02-28 上海济煜医药科技有限公司 吲哚化合物的制备、应用及用途
WO2024049977A1 (en) * 2022-08-31 2024-03-07 Chinook Therapeutics, Inc. Substituted indole compounds and methods of use thereof
JP2025530222A (ja) * 2022-09-10 2025-09-11 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ２－置換ピペリジン誘導体、その製造方法及び医薬的用途
KR20250107882A (ko) * 2022-11-14 2025-07-14 노파르티스 파르마 아게 보체 인자 b 억제제의 고체 형태
TWI869080B (zh) * 2022-11-29 2025-01-01 大陸商上海濟煜醫藥科技有限公司 苯並螺環吲哚化合物的製備及用途
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition
EP4650351A1 (en) * 2023-01-09 2025-11-19 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Inhibitor of complement factor b
AU2024221845A1 (en) * 2023-02-16 2025-09-11 Haisco Pharmaceutical Group Co., Ltd. Salt of benzo-nitrogen heteroaromatic ring derivative, crystalline form, and pharmaceutical use thereof
EP4670719A1 (en) * 2023-02-22 2025-12-31 Haisco Pharmaceutical Group Co., Ltd. PHARMACEUTICAL COMPOSITION OF A HETEROAROMATIC BENZO-NITROGEN RING DERIVATIVE AND ITS USE IN MEDICINE
WO2024222852A1 (zh) * 2023-04-27 2024-10-31 上海翰森生物医药科技有限公司 一种哌啶基吲哚化合物的盐及其制备方法
WO2025008451A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
AU2024290587A1 (en) 2023-07-04 2026-02-19 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors
EP4739667A2 (en) 2023-07-06 2026-05-13 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
TWI896250B (zh) * 2023-07-26 2025-09-01 大陸商上海美悦生物科技發展有限公司 螺環烯基類或氮雜烯基類化合物及其藥物組合物、製備方法和用途
TW202517258A (zh) * 2023-09-20 2025-05-01 大陸商上海美悦生物科技發展有限公司 雜環化合物在製備預防和／或治療腎臟疾病的藥物中的用途
TW202535375A (zh) * 2023-12-05 2025-09-16 大陸商西藏海思科製藥有限公司 苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors
WO2025256647A1 (zh) * 2024-06-14 2025-12-18 润尔眼科药物（广州）有限公司 化合物及其医药用途
WO2026008073A1 (zh) * 2024-07-05 2026-01-08 南京正大天晴制药有限公司 补体因子b抑制剂的剂量组合物
WO2026069246A1 (en) * 2024-09-30 2026-04-02 Novartis Ag Complement factor b inhibitors and uses thereof
CN121949280A (zh) * 2024-10-31 2026-05-01 甫康（上海）健康科技有限责任公司 一种多取代吲哚类化合物及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515976A (ja) * 2012-05-04 2015-06-04 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
JP2016526576A (ja) * 2013-07-15 2016-09-05 ノバルティス アーゲー ピペリジニル−インドール誘導体および補体因子ｂ阻害剤としてのその使用
JP2019527203A (ja) * 2016-06-27 2019-09-26 アキリオン ファーマシューティカルズ，インコーポレーテッド 医学的障害を治療するためのキナゾリン及びインドール化合物
WO2022028527A1 (zh) * 2020-08-07 2022-02-10 上海美悦生物科技发展有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
WO2023072197A1 (en) * 2021-10-27 2023-05-04 Hansoh Bio Llc Piperidinyl indole derivatives, preparation methods and medicinal uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2867225B1 (en) * 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CR20230614A (es) 2021-06-03 2024-02-01 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos
US20240294517A1 (en) 2021-06-24 2024-09-05 Syngenta Crop Protection Ag 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
CA3226387A1 (en) 2021-07-26 2023-02-02 Joel D. Moore Rock2 inhibitors and uses thereof
AR127922A1 (es) 2021-12-15 2024-03-13 Syngenta Crop Protection Ag Derivados heterocíclicos bicíclicos microbiocidas
US20250326757A1 (en) 2022-05-26 2025-10-23 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515976A (ja) * 2012-05-04 2015-06-04 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
JP2016526576A (ja) * 2013-07-15 2016-09-05 ノバルティス アーゲー ピペリジニル−インドール誘導体および補体因子ｂ阻害剤としてのその使用
JP2019527203A (ja) * 2016-06-27 2019-09-26 アキリオン ファーマシューティカルズ，インコーポレーテッド 医学的障害を治療するためのキナゾリン及びインドール化合物
WO2022028527A1 (zh) * 2020-08-07 2022-02-10 上海美悦生物科技发展有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
WO2023072197A1 (en) * 2021-10-27 2023-05-04 Hansoh Bio Llc Piperidinyl indole derivatives, preparation methods and medicinal uses thereof

Also Published As

Publication number Publication date
BR112023025235A2 (pt) 2024-02-27
DOP2023000263A (es) 2024-02-29
US12617774B2 (en) 2026-05-05
CN120081822A (zh) 2025-06-03
CL2023003591A1 (es) 2024-06-28
WO2022256586A3 (en) 2023-01-12
PE20250114A1 (es) 2025-01-16
EP4346812A2 (en) 2024-04-10
US20240287034A1 (en) 2024-08-29
CO2023016557A2 (es) 2024-02-26
PH12023553130A1 (en) 2024-03-11
CA3222144A1 (en) 2022-12-08
AU2022283903A1 (en) 2023-11-30
CR20230564A (es) 2024-02-27
US20250289804A1 (en) 2025-09-18
ECSP23090260A (es) 2024-02-29
EP4346812A4 (en) 2025-04-09
KR20240017004A (ko) 2024-02-06
JOP20230315A1 (ar) 2023-11-30
MX2023014274A (es) 2024-04-22
WO2022256586A2 (en) 2022-12-08
IL308835A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
US12617774B2 (en) Substituted indole compounds and methods of use thereof
JP7635145B2 (ja) Ｇｌｐ－１ｒアゴニスト及びその使用
AU2022329230A1 (en) Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
US9834541B2 (en) 2-aminopyridine compounds
WO2024049977A1 (en) Substituted indole compounds and methods of use thereof
KR20180021860A (ko) Magl 억제제로서의 1,1,1-트리플루오로-3-히드록시프로판-2-일 카르바메이트 유도체 및 1,1,1-트리플루오로-4-히드록시부탄-2-일 카르바메이트 유도체
EA028722B1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
CN103748087A (zh) 吲唑和吡咯并吡啶衍生物和其药学用途
BR102015024618A2 (pt) compostos inibidores de quinase de ligação de tank
TW201211053A (en) Spiro compound and drug for activating adiponectin receptor
CN117500499A (zh) 经取代的吲哚化合物及其使用方法
KR20230051500A (ko) Alk5 억제제로서 피리다진일 아미노 유도체
JP7661533B2 (ja) Ｎｒｆ２活性化作用を有する含窒素複素環化合物
JP2025060769A (ja) アミノアジンアミド
EP4727934A1 (en) Trem2 agonists
KR20240165360A (ko) 에모파밀 결합 단백질 억제제 및 이의 용도
EA052249B1 (ru) Замещенные индольные соединения и способы их применения
US12122750B2 (en) AT2R antagonists and uses thereof
TW202542138A (zh) 與含ｐａｔａｔｉｎ樣磷脂酶結構域蛋白３ＩＭ結合的化合物及其用於治療肝病之用途
KR20260061216A (ko) 에모파밀 결합 단백질 억제제로서의 피라졸릴 화합물
OA18588A (en) 1,1,1-Trifluoro-3-Hydroxypropan-2-yl Carbamate Derivatives and 1,1,1-Trifluoro-4Hydroxybutan-2-yl Carbamate Derivatives as Magl Inhibitors.

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260417